Incyte is trading 21.63% down now at $97.69 after no clear company-specific catalyst was identified in available September 22, 2026 coverage.

  • Recent reporting focused on pipeline progress, the September 26 FDA decision involving partnered drug zilurgisertib, and an expanded Australian Opzelura partnership.
  • The broader market is mixed, so macro sentiment does not clearly explain the unusually large pre-market decline.
  • Recheck for a delayed filing, regulatory update, or data release.